Available from: Acknowledgments and Disclosures The authors would like to thank Bengt-Olof Axelsson, Magnus Bernt, Dorthe Kot Engelund, Frederik Gustafsson, Morten Hach, Mattias Hansson, Karen Hauda, Susanne Hostrup, Heidi Jensen, Magdalena Renee Johansen, Inger Mollerup, Griffin E
While muscle cramps are not listed as a common side effect in FDA labeling, some patients report experiencing them during treatment
Because compounded GLP-1 medications vary in quality and safety, medical oversight is essential for effective and responsible treatment
These results shed light on the role that GIP receptor agonism plays in the therapeutic profile of dual receptor agonism and provide mechanistic explanations for the clinical effectiveness of tirzepatide [80]
The good news is that this is not inevitable